## Douglas E Brenneman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4751557/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-Inflammatory Properties of KLS-13019: a Novel GPR55 Antagonist for Dorsal Root Ganglion and Hippocampal Cultures. Journal of Molecular Neuroscience, 2022, 72, 1859-1874.	2.3	4
2	Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLSâ€13019 in mouse models of pain and reinforcement. British Journal of Pharmacology, 2021, 178, 3067-3078.	5.4	13
3	Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity. Journal of Molecular Neuroscience, 2019, 68, 603-619.	2.3	17
4	Pharmacological Comparisons Between Cannabidiol and KLS-13019. Journal of Molecular Neuroscience, 2018, 66, 121-134.	2.3	15
5	Pharmacological Effects on Ceroid Lipofuscin and Neuronal Structure in Cln3 â^†ex7/8 Mouse Brain Cultures. Journal of Molecular Neuroscience, 2017, 63, 100-114.	2.3	5
6	Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability. ACS Medicinal Chemistry Letters, 2016, 7, 424-428.	2.8	36
7	Small-Molecule Anticonvulsant Agents with Potent In Vitro Neuroprotection and Favorable Drug-Like Properties. Journal of Molecular Neuroscience, 2014, 52, 446-458.	2.3	5
8	Small Molecule Anticonvulsant Agents with Potent In Vitro Neuroprotection. Journal of Molecular Neuroscience, 2012, 47, 368-379.	2.3	6
9	Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of <i>N</i> -((Benzo[ <i>b</i> ]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies. Journal of Medicinal Chemistry, 2009, 52, 7528-7536.	6.4	32